PANACEA Feasibility Study to Assess the Efficacy of BurstDR Spinal Cord Stimulation (SCS)

Inclusion Criteria: * Male or female participants aged 18 years or older (no upper age limit) and willing to provide informed consent * Participant is able and willing to comply with the follow-up schedule and protocol * Participants diagnosed with persistent refractory visceral pain secondary to chronic pancreatitis for at least 6 months with or without dermal hyperalgesia or allodynia * Minimum baseline pain score of 6 on eleven point NRS scale (0-10) for their visceral pain * Previously tried and failed at least one conservative treatment for chronic pain including but not limited to pharmacological therapy, physical therapy and interventional pain procedures for persistent pain * Been deemed suitable for the study by the pancreatic or pain MDT * Total daily dose of opioids equivalent to ≤120mg of Morphine or 50% reduction in opioid dose. If the patients are taking more than this dose, they will be offered a referral to our opioid reduction clinic to achieve the target opioid dose and the baseline opioid will be taken as the dose on referral * In the investigators opinion, the patient is a suitable candidate for Spinal Cord Stimulation Exclusion Criteria: * Female participants of childbearing potential who are pregnant/nursing or plan to become pregnant during the course of the trial * Escalating or changing pain condition within the past month as evidenced by investigator examination * Sphlanchnectomy or radiofrequency treatment within the past 6 months * Currently has an active implantable device including pacemakers, spinal cord stimulator or intrathecal drug delivery system * In the investigators opinion has an active infection * Participated in another clinical investigation within 30 days * Medical co-morbidities that preclude surgical intervention * Patient is incapable of understanding or operating the patient programmer handset * Patient is morbidly obese (BMI ≥ 40) * Participant has a current or previous condition, which will probably require MRI investigation sometime in the following 2 years * Participant has had a spinal surgical procedure or has spinal pathology that would significantly impede lead implantation at the level planned for implantation * Participant has another persistent painful condition other than persistent refractory visceral pain secondary to chronic pancreatitis. * History of alcohol abuse in the last year or IV drug abuse in the last three years. * No increases of more than 40% from baseline amylase and lipases